Journal of Comparative Effectiveness Research Publishes Pivotal Level 1 Evidence Comparing activLŽ Artificial Disc to ProDisc-L, Fusion and Conservative Care


Center Valley, PA (September 28, 2017) – Aesculap Implant Systems, LLC and Cornerstone Research Group, Inc. today announced the publication of a Network Meta-Analysis (NMA) which was conducted to measure the varying impacts of different treatment modalities for single-level lumbar Degenerative Disc Disease (DDD). The NMA results show activL Artificial Disc is more likely to address patient disability, pain and satisfaction than previous standards of care for Degenerative Disc Disease such as ProDisc-L and fusion.

While NMAs are becoming increasingly relied upon globally and across medical specialties, this NMA is pioneering in that it marks the first of its kind performed to compare device-to-device treatment modalities for the lumbar spine. The study, published in the Journal of Comparative Effectiveness Research, pools outcomes from six randomized controlled trials studying the DDD patient to compare treatment modalities that had not previously been directly compared. The outcomes will be used by global Health Technology Assessments (HTAs), payers and healthcare providers to significantly aid in the clinical management of this otherwise highly-burdensome patient population.

“Our review of the literature revealed limited data comparing newer TDR devices with other existing treatment modalities, so an NMA was conducted,” said Chris Cameron, PhD, Director of Evidence Synthesis at Cornerstone Research Group and co-author of the study. Cameron and team have been involved in over 100 similar studies including the development of the PRISMA-NMA extension guidelines that were recently published in the Annals of Internal Medicine.

Using Bayesian statistics, the NMA allowed for estimates of comparative efficacy for treatment modalities that have not been compared directly in clinical trials, as well as estimates of the probability that a treatment is best, second best, and so on for a particular outcome. Among the comparators included in the NMA, activL Artificial Disc was demonstrated to be the most effective means to address chronic back pain sufferers in the outcomes of ODI success, back pain and patient satisfaction.

Jack Zigler, MD of the Center for Disc Replacement at the Texas Back Institute and lead author of the publication stated, “Broader view afforded by an NMA asserts that properly-selected patients do better with activL than fusion or conservative care or even first-generation lumbar discs.”

The study authors have made the full text of the manuscript available at https://www.futuremedicine.com/doi/10.2217/cer-2017-0047 in an effort to improve healthcare providers’ understanding of sound NMA methods and how they can be applied to inform clinical practices to the benefit of the patient.

Contact:
Judy Marushak
Senior Project Manager, Corporate Communications
Aesculap Implant Systems, LLC
office: 610-984-9242
toll-free: 800-258-1946, x5242
cell: 610-217-4964
judy.marushak@aesculapusa.com

 
 

Contact Us

For inquiries in the USA, US Territories and Canada.

Don't fill out the following text fields (spam catchers):
Please check the box below to confirm you wish to send this form.

 

 

Click here for locations outside the USA, US Territories and Canada >>

Literature Website